|
Dear Friends of AHP,
We want to make you aware of a study investigating the effects of an agaricus-turkey tail mycelium biomass product (Host Defense) in conjunction with a COVID-19 vaccine. The study is an extension of a previous study published January 31 in BMC Immunology and reported in AHP’s News & Views on March 4. In the previous study, the mycelium preparation reduced adverse effects of the COVID-19 vaccine and maintained the desired immune response. In a preliminary review of this study, Polypore Mushroom Mycelia for Treatment of Active COVID-19 Infection: A Randomized Clinical Trial, the same preparation (Host Defense) was given in conjunction with a COVID vaccine. A significant reduction in severity of COVID symptoms (coughing, sore throat, and muscle aches) was reported.
A pre-print version of the paper can be accessed at “Med Archives” at the following link. The article includes a comprehensive table showing serum, viral load, and symptom efficacy.
https://www.medrxiv.org/content/10.64898/2026.06.01.26354267v1.
The first paper can be accessed at https://link.springer.com/epdf/10.1186/s12865-026-00809-9?sharing_token=DBGXRyKnkSezmsHXmRfPaG_BpE1tBhCbnbw3BuzI2RNeZJzn2bSJY0Euzm0kHKhDRFdopXn5KJGihCS-vqT9OCKjG0wKmGR7NJ_D9y2gHa0nXQsLjpytI-sFxYQgRuKX-J2GtUN7vpYGRsoh1NCixHHoX3-FmP_Z58QMjR7Esck%3D
We congratulation the researchers and Host Defense who are currently or soon will be conducting in vitro tests on other viruses, including Ebola, bird flu (H5N1), and pox. These papers represent a unique contribution to the mushroom product literature.
For more information about AHP, or if you are interested in becoming an AHP member, please visit herbal-ahp.org. Be sure to follow us on LinkIn at https://www.linkedin.com/company/herbal-ahp
| 
